Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 15
HOS-108884 · Präparat HOS-093083
For patients who have completed the ramp-up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions). Patients should be closely monitored for signs related to venetoclax toxicities. Anticoagulants Warfarin Warfarin: It is recommended that INR Concentrations may be affected (international normalised ratio) be when co-administered with monitored. lopinavir/ritonavir due to CYP2C9 induction. Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban AUC: ↑ 153% and Kaletra may increase (Ritonavir 600 mg twice Cmax: ↑ 55% rivaroxaban exposure which may daily) Due to CYP3A and P-gp increase the risk of bleeding. inhibition by lopinavir/ritonavir. The use of rivaroxaban is not recommended in patients receiving concomitant treatment with Kaletra (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): venetoclax (HOS-086143) rivaroxaban (HOS-086236) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 5c75313975c3d550f186691732eade756ee17474da9f35bb7423f4bee955c1ce · Zeichen 21495–23493 im Abschnitt